Ontology highlight
ABSTRACT: Purpose
Although immune checkpoint inhibitors (ICI) are generally the preferred first-line treatment for metastatic BRAF V600-mutated melanoma, a subgroup that remains incompletely defined requires initial tumor control with BRAF/MEK-targeted therapy (TT). The purpose of this study was to evaluate circulating thymidine kinase activity (TKa), a blood-based marker of cellular proliferation, as a biomarker of outcome and treatment sequencing in patients enrolled in the randomized phase II SECOMBIT trial (NCT02631447).Patients and methods
Serum TKa was analyzed in samples from patients at baseline and during treatment. Patients were stratified by median baseline TKa, and survival outcomes were compared across three strategies for first- and second-line treatments: TT followed b
SUBMITTER: Helgadottir H
PROVIDER: S-EPMC13669722 | biostudies-literature | 2026 Oct
REPOSITORIES: biostudies-literature